Cadence
  • SERVICES
    • Market Research
    • Medical Communications
    • Patient Centered Care
  • INSIGHTS
  • ABOUT
  • CONTACT
  • SERVICES
    • Market Research
    • Medical Communications
    • Patient Centered Care
  • INSIGHTS
  • ABOUT
  • CONTACT
Zachary Moore
By Zachary Moore In Approval Blog

Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC

On February 16, 2018 the FDA approved Imfinzi® (durvalumab) as a consolidation treatment for patients with stage III non-small cell…
Read More

CADENCE APPROVAL BLOG

Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC

Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer

Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma

Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma

Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC

Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma

Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Blinatumomab for Patients with MRD-positive B-cell Precursor ALL

Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML

Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer

Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer

Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors

Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer

Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC

Third time on the Inc. 5000, Ranking No. 3160 Learn More

Terms of Use | Privacy Policy

TRUSTe
"We use cookies to give you the best possible experience on our website. To learn more about cookies and how we use them please see our cookie policy here. See more information on changing cookie preferences here. Please be aware the site may not function properly without cookies. [ ] I consent.”
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT